Drug intelligence / Profile preview

FD-002

Development stage: Preclinical
Lead developer: Chengdu FenDi Pharmaceutical
Modality: Molecular Glues → Targeted Protein Degraders (TPDs) → Small Molecules

Overview

FD-002 is a small molecule molecular glue developed by Chengdu FenDi Pharmaceutical that functions as a P53 activator. It is designed to restore or enhance the tumor-suppressive activity of the P53 protein, which is frequently inactivated in hematologic malignancies. The drug was discovered using the company's proprietary PRODED™ (Protein Degradation Drug) technology platform, which integrates artificial intelligence (AI) with targeted protein degradation (TPD) logic. FD-002 is currently in the optimization and preclinical discovery stage, with primary development efforts focused on treating Acute Myeloid Leukemia (AML) and Non-Hodgkin Lymphoma (NHL).

Targets

TP53 (Cellular Tumor Antigen p53 R175H)

Beyond the preview

Go deeper on FD-002.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on FD-002.

Explore the full profile